NCT06966674

No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track

Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Kafrelsheikh University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.

Detailed description

ST-segment-elevation myocardial infarction (STEMI) is most commonly caused by rupture or erosion of an atherosclerotic plaque, resulting in acute occlusion of the coronary artery, and the preferred reperfusion strategy is primary percutaneous coronary intervention (PCI). The no-reflow phenomenon is one of the most common causes of adverse cardiovascular events in patients STEMI. In recent years, mechanical or pharmacological treatment strategies including adjunctive administration of glycoprotein IIb/IIIa inhibitors (GPI) have been proposed in patients with STEMI.

Conditions

• No-Reflow
• STEMI
• Intracoronary
• Tirofiban

Interventions

Type	Name	Description
DRUG	Intracoronary tirofiban	Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).
DRUG	Saline 0.9%	Patients will receive intracoronary saline 0.9% solution as a control group.

Timeline

• Start date: 2025-05-12
• Primary completion: 2025-10-01
• Completion: 2025-10-01
• First posted: 2025-05-13
• Last updated: 2025-05-13

Locations

1 site across 1 country: Egypt